Pre-IPO Intellectual Property Due Diligence: Patents, Trademarks, and Trade Secrets

The Hong Kong Stock Exchange’s (HKEX) Listing Committee has sharpened its scrutiny of intellectual property (IP) assets in listing applications, a trend that intensified following the publication of the 2024 HKEX IPO Review and the SFC’s 2025 Enforcement Report. For companies preparing to list on the Main Board or GEM, a superficial IP audit is no longer sufficient. The SFC’s 2025 report highlighted that 12% of enforcement actions in the past year involved misrepresentations of patent portfolios or trade secret ownership, directly impacting sponsor liability under the Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (SFC Code, Chapter 9, paragraph 9.3). This shift is not merely procedural; it reflects a fundamental recalibration of how the HKEX assesses a company’s core value proposition and competitive moat. An applicant’s failure to demonstrate clean, enforceable, and defensible IP rights can now trigger a “red flag” that stalls the listing process, or worse, exposes sponsors to disciplinary action. This article dissects the three critical pillars of pre-IPO IP due diligence—patents, trademarks, and trade secrets—providing a technical roadmap for sponsors, counsel, and C-suite executives navigating the 2025-2026 listing window.

The Regulatory Framework: Why IP Due Diligence Is Non-Negotiable

The HKEX’s Listing Rules, specifically Chapter 8 (Qualifications for Listing), require applicants to demonstrate a sustainable business model. The SFC’s 2025 Enforcement Report explicitly noted that “inadequate verification of core intellectual property assets” was a recurring theme in sponsor failures, with three sponsors fined a total of HKD 45 million for deficiencies in IP-related due diligence. The SFC Code, Chapter 17, paragraph 17.6, mandates that sponsors must “take reasonable steps to satisfy themselves that the statements made in the listing document are accurate and complete in all material respects.” This obligation extends directly to verifying patent filings, trademark registrations, and the existence of trade secret protection protocols.

The HKEX’s 2024 Listing Decision LD124-2024 further clarified that for companies in technology, biotech, or consumer goods sectors, IP is considered a “key performance indicator” under Listing Rule 8.05(3). The Exchange expects sponsors to provide a “legal opinion on the validity and enforceability of the material IP rights in each jurisdiction of operation.” This is not a cursory review; it requires engagement with patent attorneys in the PRC, the United States, and other key markets. The consequence of non-compliance is a formal “deficiency letter” (LD124-2024, paragraph 32), which can delay the listing timetable by 8-12 weeks.

Patents: Verification, Ownership, and Freedom to Operate

Patent due diligence is the most technically demanding component, requiring a forensic examination of the applicant’s patent portfolio against the claims in the prospectus (招股書). The process must confirm that the patents are not only granted but also valid and enforceable in the jurisdictions where the company operates or intends to operate.

Ownership Chain and Assignment Verification

The first step is to verify the unbroken chain of title from the inventor to the applicant. For PRC-based companies, this is particularly complex due to the prevalence of university spin-offs and employee inventions. The PRC Patent Law (Article 6) presumes that inventions made in the course of employment belong to the employer, but this presumption is rebuttable. Sponsors must obtain executed assignment agreements from every named inventor, dated before the patent filing. A common deficiency, flagged in the 2024 SFC thematic review of biotech IPOs, involves missing assignments from former employees or academic supervisors. The SFC found that 8% of reviewed applications had at least one patent with an incomplete ownership chain, leading to a “material adverse finding” under Listing Rule 8.04.

For companies using a BVI or Cayman holding structure, the assignment must be recorded with the relevant patent office (CNIPA, USPTO, EPO) to perfect the security interest. The SFC Code, Chapter 9, paragraph 9.5, requires sponsors to obtain “confirmation from legal counsel in each relevant jurisdiction that the assignments are valid and binding.” This often involves a review of the company’s IP register and cross-referencing it with the corporate records of the BVI or Cayman entity.

Freedom to Operate (FTO) Analysis

Beyond ownership, the applicant must demonstrate that its products or processes do not infringe on third-party patents. An FTO analysis is not a standard patentability search; it is a legal risk assessment that identifies potential blocking patents. The HKEX’s 2024 Listing Decision LD124-2024 explicitly states that for a company whose “primary revenue is derived from a patented technology,” the sponsor must provide an FTO opinion from a qualified patent attorney. The opinion must cover all major markets, including the PRC, the US (under 35 U.S.C. § 271), and the EU.

The analysis should include a claim chart mapping the company’s product to the claims of any potentially relevant third-party patents. A finding of “high risk” of infringement (defined as a >50% probability in a litigation scenario) must be disclosed in the prospectus risk factors under Listing Rule 11.06. Failure to do so constitutes a material omission. The sponsor’s working papers must document the search strategy, the databases used (e.g., Derwent Innovation, PatSnap), and the rationale for excluding any patents.

Patent Term and Maintenance

Sponsors must verify that all material patents are in force and have not lapsed due to non-payment of maintenance fees. The PRC patent system requires annual renewal fees, and a lapse can be fatal. The due diligence should include a review of the patent annuity payment history for the past three years, confirmed by the patent agent. For patents nearing expiry (within 5 years), the sponsor must assess the impact on revenue, as per HKEX Guidance Letter GL94-18 (paragraph 4.2). If a patent is the sole source of revenue, the listing may be deemed “not suitable” under Listing Rule 8.04.

Trademarks: Brand Protection and Cross-Border Risk

Trademark due diligence focuses on the company’s brand assets, which are often the most visible IP in a prospectus. The HKEX and SFC have increasingly focused on “bad faith” trademark filings and the risk of brand dilution in cross-border operations.

Registration Coverage and Classes

The sponsor must verify that the company’s core trademarks are registered in all material jurisdictions. For a Hong Kong-listed company with operations in the PRC, this means checking registrations with the China National Intellectual Property Administration (CNIPA) and the Hong Kong Intellectual Property Department (IPD). The SFC Code, Chapter 17, paragraph 17.8, requires the sponsor to obtain “a certified copy of the trademark registration certificate from each relevant office.”

The due diligence must also confirm that the registrations cover the correct Nice Classification classes. A common error is registering a trademark for “clothing” (Class 25) when the company’s primary revenue comes from “retail services” (Class 35). The sponsor must map each trademark registration to the specific products or services generating revenue, as disclosed in the prospectus. Any gap in coverage must be disclosed as a risk factor.

”Bad Faith” Filings and Opposition Risks

The PRC operates a “first-to-file” system, making it susceptible to bad faith filings by third parties. The sponsor must conduct a search for any pending oppositions or invalidation actions against the applicant’s trademarks. The SFC’s 2025 Enforcement Report cited a case where a company’s main trademark was under opposition at CNIPA, and the sponsor failed to disclose this in the prospectus. The SFC imposed a fine of HKD 8 million on the sponsor for “failure to identify a material litigation risk.” The due diligence must include a review of the CNIPA trademark database for any “identical or similar” marks filed by unrelated parties, and an assessment of the likelihood of a successful opposition.

Domain Names and Social Media Handles

While not a formal IP right, domain names and social media handles are increasingly treated as brand assets by the HKEX. Listing Rule 2.03 requires the applicant to “conduct its business in a manner which is consistent with the interests of the investing public.” If a company’s primary domain name is owned by a former director or an unrelated third party, this creates a “control risk.” The sponsor must verify that the domain name is registered in the company’s name and that the registration is current. A failure to secure the domain name can lead to a “deficiency letter” under Listing Decision LD124-2024.

Trade Secrets: The Invisible Asset Under Scrutiny

Trade secrets are the most difficult IP to verify, as they lack registration. The HKEX and SFC have focused on whether an applicant has “adequate procedures” to protect its trade secrets, particularly in the context of employee mobility and cross-border data flows.

Identification and Documentation

The first step is to identify the company’s trade secrets. This is not a generic statement; the sponsor must document a list of specific, identifiable information that constitutes a trade secret, such as customer lists, manufacturing processes, or proprietary algorithms. The SFC Code, Chapter 9, paragraph 9.10, requires the sponsor to “obtain a written representation from the directors identifying the material trade secrets and the steps taken to protect them.” This representation must be supported by evidence, such as confidentiality agreements, employee handbooks, and access logs.

Confidentiality Agreements and Employee Covenants

The sponsor must review all confidentiality agreements (NDAs) with employees, contractors, and business partners. The agreements must be “reasonable in scope and duration” under the relevant law (e.g., the PRC Anti-Unfair Competition Law, Article 9). A common deficiency is a “boilerplate” NDA that does not specifically identify the trade secrets. The sponsor must also review post-employment restrictive covenants (non-compete and non-solicitation clauses). In the PRC, non-compete clauses are enforceable only if the employee receives compensation (PRC Employment Contract Law, Article 23). The sponsor must verify that the company has paid such compensation, or the covenant is void.

Physical and Electronic Security Measures

The HKEX expects the applicant to have “adequate security measures” to prevent unauthorized access to trade secrets. The sponsor must conduct a site visit and review the company’s IT security protocols. This includes password policies, data encryption, access controls, and physical security (e.g., locked filing cabinets). The SFC’s 2025 Enforcement Report noted that a failure to maintain “basic cybersecurity hygiene” was a factor in two cases where trade secrets were misappropriated, leading to a material adverse change in the company’s financials. The sponsor’s working papers must document the findings of the site visit and any remediation steps taken.

Cross-Border Data Transfer Risks

For companies with operations in the PRC, the transfer of trade secrets across borders is subject to the PRC Cybersecurity Law (Article 37) and the Personal Information Protection Law (PIPL). The sponsor must verify that the company has obtained the necessary approvals from the Cyberspace Administration of China (CAC) for any cross-border data transfer that includes trade secrets. A failure to do so is a legal risk that must be disclosed in the prospectus under Listing Rule 11.06. The HKEX’s 2024 Guidance Letter GL94-18 specifically addresses this issue for biotech companies, requiring a “legal opinion on the compliance of cross-border data transfers.”

Actionable Takeaways

• Conduct a full patent ownership chain audit at least six months before the A1 filing, obtaining executed assignment agreements from all inventors and recording them with the relevant patent offices (CNIPA, USPTO, EPO) to pre-empt SFC scrutiny under the SFC Code, Chapter 9.
• Commission a Freedom to Operate (FTO) opinion from a qualified patent attorney for the company’s primary revenue-generating products, covering the PRC, the US, and the EU, as mandated by HKEX Listing Decision LD124-2024.
• Verify trademark registrations in all material jurisdictions (PRC, Hong Kong, US) and map them to the specific Nice Classification classes that align with revenue streams, ensuring no gaps that would require a risk factor disclosure.
• Document a formal trade secret inventory with a board representation, supported by employee confidentiality agreements that include reasonable post-employment covenants and proof of compensation under PRC Employment Contract Law, Article 23.
• Review cross-border data transfer protocols for compliance with the PRC Cybersecurity Law and PIPL, obtaining a legal opinion on CAC approvals if trade secrets are transferred outside the PRC.